Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Gains from Investment Securities (2022 - 2025)

Historic Gains from Investment Securities for Phathom Pharmaceuticals (PHAT) over the last 4 years, with Q3 2025 value amounting to $9.5 million.

  • Phathom Pharmaceuticals' Gains from Investment Securities rose 4657.52% to $9.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.5 million, marking a year-over-year increase of 4657.52%. This contributed to the annual value of $6.2 million for FY2024, which is 3537.26% up from last year.
  • Latest data reveals that Phathom Pharmaceuticals reported Gains from Investment Securities of $9.5 million as of Q3 2025, which was up 4657.52% from $9.7 million recorded in Q2 2025.
  • Over the past 5 years, Phathom Pharmaceuticals' Gains from Investment Securities peaked at $9.7 million during Q2 2025, and registered a low of -$5.3 million during Q4 2023.
  • Over the past 4 years, Phathom Pharmaceuticals' median Gains from Investment Securities value was $5.6 million (recorded in 2022), while the average stood at $4.0 million.
  • In the last 5 years, Phathom Pharmaceuticals' Gains from Investment Securities crashed by 254626.87% in 2023 and then soared by 92029.03% in 2024.
  • Quarter analysis of 4 years shows Phathom Pharmaceuticals' Gains from Investment Securities stood at -$201000.0 in 2022, then plummeted by 2546.27% to -$5.3 million in 2023, then soared by 83.15% to -$896000.0 in 2024, then soared by 1154.95% to $9.5 million in 2025.
  • Its Gains from Investment Securities was $9.5 million in Q3 2025, compared to $9.7 million in Q2 2025 and $7.0 million in Q1 2025.